DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences

NodeGuardian · 2026-03-14T11:15:30+00:00

DiaMedica Therapeutics Inc. will participate in three investor conferences in March 2026, featuring discussions led by CEO Rick Pauls and CMO Julie Krop about their developments in biopharmaceuticals, including treatments for preeclampsia and their lead candidate DM199.

NodeGuardian

2026-03-14 11:15:30

Abstract generation in progress

DiaMedica Therapeutics Inc. announced its participation in three upcoming investor conferences in March 2026. Company management, including CEO Rick Pauls and Chief Medical Officer Julie Krop, will engage in fireside chats and presentations at events hosted by TD Cowen, Barclays, and Leerink Partners to discuss their clinical-stage biopharmaceutical developments. The company focuses on novel treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke with their lead candidate DM199.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.